H.C. Wainwright lowered the firm’s price target on OnKure Therapeutics (OKUR) to $34 from $40 and keeps a Buy rating on the shares. The firm cites the company’s equity raise for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR:
- Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
- Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
- OnKure Therapeutics Reports Progress and Financials